Wird geladen...

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis

Dalfampridine extended release (ER) 10 mg is an oral tablet form of the potassium (K(+)) channel-blocking compounded dalfampridine, also known as fampridine, and chemically 4-aminopyridine or 4-AP, which received regulatory approval in the United States for the treatment of walking in patients with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: Hayes, Keith C
Format: Artigo
Sprache:Inglês
Veröffentlicht: Dove Medical Press 2011
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3090287/
https://ncbi.nlm.nih.gov/pubmed/21573085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S10469
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!